Page 9 - டோ ஜோன்ஸ் நிலைத்தன்மை குறியீடுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

F. Hoffmann-La Roche Ltd: New data for Roche s Hemlibra reinforce safety profile in people with haemophilia A IIIb haemophilia Hemlibra 1 STASEY is one of the largest open-label studies primarily assessing safety and tolerability of a medicine for people with haemophilia Hemlibra also continued to demonstrate effective bleed control with a high proportion of participants (82.6%) achieving zero treated bleeds 1 Basel, 19 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the final analysis of the phase IIIb STASEY study, which confirm the favourable safety profile of Hemlibra (emicizumab), consistent with the phase III HAVEN clinical programme. 1,2,3,4 In the analysis, no new safety signals were identified with longer-term Hemlibra treatment in adults and adolescents with haemophilia A with inhibitors to factor VIII, the clotting protein that is missing or defective in people with haemophilia A. The data were presented at the virtual International

Glasgow cityUnited kingdomUnited statesNathalie meetzLevi garrawayJon kaspar bayardKarl mahlerMabthera rituxanGazyva gazyvaroSabine borngrGerard tobinBruno eschliVenclexta venclyxtoBirgit masjostLoren kalmPatrick barth